BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther. 2006;23:1055-1065. [PMID: 16611265 DOI: 10.1111/j.1365-2036.2006.02889.x] [Cited by in Crossref: 125] [Cited by in F6Publishing: 109] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Kim BK. Transient elastography can be integrated into routine clinical practice for the evaluation of portal hypertension? Clin Mol Hepatol 2017;23:27-30. [PMID: 28349679 DOI: 10.3350/cmh.2017.0101] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
2 Bano S, Qureshi J, Raza A, Zafar Hashmi K. Thrombocytopenia as a Clinical Manifestation of Hepatitis C Among Patients With a Positive Anti-HCV Test. Int J Infect 2016;3. [DOI: 10.17795/iji-35094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
3 Jhaveri KS, Hosseini-Nik H, Sadoughi N, Janssen H, Feld JJ, Fischer S, Menezes R, Cheung AC. The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis. Eur Radiol. 2019;29:1039-1047. [PMID: 30051141 DOI: 10.1007/s00330-018-5619-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
4 Afdhal NH, Dusheiko GM, Giannini EG, Chen P, Han K, Mohsin A, Rodriguez–torres M, Rugina S, Bakulin I, Lawitz E, Shiffman ML, Tayyab G, Poordad F, Kamel YM, Brainsky A, Geib J, Vasey SY, Patwardhan R, Campbell FM, Theodore D. Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy. Gastroenterology 2014;146:442-452.e1. [DOI: 10.1053/j.gastro.2013.10.012] [Cited by in Crossref: 88] [Cited by in F6Publishing: 76] [Article Influence: 12.6] [Reference Citation Analysis]
5 Boyer TD, Habib S. Big spleens and hypersplenism: fix it or forget it? Liver Int. 2015;35:1492-1498. [PMID: 25312770 DOI: 10.1111/liv.12702] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
6 Feng B, Zhang W, Luo BF, Song GJ, Wang J, Jin Q, Qin H, Wei L. Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients. World J Gastroenterol 2014; 20(41): 15387-15397 [PMID: 25386089 DOI: 10.3748/wjg.v20.i41.15387] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
7 Barton CA. Treatment of Coagulopathy Related to Hepatic Insufficiency: . Critical Care Medicine 2016;44:1927-33. [DOI: 10.1097/ccm.0000000000001998] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Rizzetto M, Grotzinger K, Theodore D, Demuth D, Irving WL, Manns M, Roughley A, Forssen UM. Reasons for nonuse of antiviral treatment in patients with chronic hepatitis C infection and thrombocytopaenia: a retrospective chart review from five European countries. J Viral Hepat 2014;21:e129-34. [PMID: 24698004 DOI: 10.1111/jvh.12256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Ishikawa T, Okoshi M, Tomiyoshi K, Kojima Y, Horigome R, Imai M, Nozawa Y, Iwanaga A, Sano T, Honma T, Yoshida T. Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia. Hepatol Res. 2019;49:590-593. [PMID: 30602063 DOI: 10.1111/hepr.13305] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
10 Djordjević J, Svorcan P, Vrinić D, Dapcević B. [Splenomegaly and thrombocytopenia in patients with liver cirrhosis]. Vojnosanit Pregl 2010;67:166-9. [PMID: 20337100 DOI: 10.2298/vsp1002166d] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
11 Surana P, Hercun J, Takyar V, Kleiner DE, Heller T, Koh C. Platelet count as a screening tool for compensated cirrhosis in chronic viral hepatitis. World J Gastrointest Pathophysiol 2021; 12(3): 40-50 [PMID: 34084591 DOI: 10.4291/wjgp.v12.i3.40] [Reference Citation Analysis]
12 Peck-Radosavljevic M, Simon K, Iacobellis A, Hassanein T, Kayali Z, Tran A, Makara M, Ben Ari Z, Braun M, Mitrut P, Yang SS, Akdogan M, Pirisi M, Duggal A, Ochiai T, Motomiya T, Kano T, Nagata T, Afdhal N. Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2). Hepatology. 2019;70:1336-1348. [PMID: 30762895 DOI: 10.1002/hep.30561] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 29.0] [Reference Citation Analysis]
13 Giannini EG, Basso M, Savarino V, Picciotto A. Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension. J Intern Med. 2009;266:537-546. [PMID: 19849774 DOI: 10.1111/j.1365-2796.2009.02130.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
14 Grotzinger KM, Younossi ZM, Giannini EG, Chen PJ, Rendas-Baum R, Theodore D. Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies. Health Qual Life Outcomes. 2016;14:49. [PMID: 27004952 DOI: 10.1186/s12955-016-0447-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
15 Kim BK, Park YN, Kim DY, Park JY, Chon CY, Han K, Ahn SH. Risk Assessment of Development of Hepatic Decompensation in Histologically Proven Hepatitis B Viral Cirrhosis Using Liver Stiffness Measurement. Digestion 2012;85:219-27. [DOI: 10.1159/000335430] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
16 Lin KH, Hsu PI, Yu HC, Lin CK, Tsai WL, Chen WC, Chan HH, Lai KH. Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts. BMC Gastroenterol 2012;12:7. [PMID: 22257364 DOI: 10.1186/1471-230X-12-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
17 Li T, Sun X, Luo F, Song S, Yu Y, Lv G. Sirolimus-Induced Delayed Severe Thrombocytopenia After Liver Transplantation: A Case Report. Transplant Proc 2020;52:1950-2. [PMID: 32444121 DOI: 10.1016/j.transproceed.2020.02.125] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Hermos JA, Altincatal A, Weber HC, Grotzinger K, Smoot KJ, Cho K, Gagnon DR, Lawler EV. Thrombocytopenia and bleeding in veterans with non-hepatitis C-related chronic liver disease. Dig Dis Sci 2013;58:562-73. [PMID: 23010745 DOI: 10.1007/s10620-012-2404-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
19 Ali RO, Moon MS, Townsend EC, Hill K, Zhang GY, Bradshaw A, Guan H, Hamilton D, Kleiner DE, Auh S, Koh C, Heller T. Exploring the Link Between Platelet Numbers and Vascular Homeostasis Across Early and Late Stages of Fibrosis in Hepatitis C. Dig Dis Sci 2020;65:524-33. [PMID: 31407130 DOI: 10.1007/s10620-019-05760-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Hermos JA, Quach L, Gagnon DR, Weber HC, Altincatal A, Cho K, Lawler EV, Grotzinger KM. Incident severe thrombocytopenia in veterans treated with pegylated interferon plus ribavirin for chronic hepatitis C infection. Pharmacoepidemiol Drug Saf 2014;23:480-8. [PMID: 24677630 DOI: 10.1002/pds.3585] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
21 Morihara D, Kobayashi M, Ikeda K, Kawamura Y, Saneto H, Yatuji H, Hosaka T, Sezaki H, Akuta N, Suzuki Y, Suzuki F, Kumada H. Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia. Hepatology Research 2009;39:439-47. [DOI: 10.1111/j.1872-034x.2008.00481.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
22 Chien C, Lin Y, Chien R, Hu C, Yen C, Lee T, Hsieh P, Lin C. Transient Elastography for Spleen Stiffness Measurement in Patients With Cirrhosis: Role in Degree of Thrombocytopenia. Journal of Ultrasound in Medicine 2016;35:1849-57. [DOI: 10.7863/ultra.15.09064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
23 Brown RS Jr, Imawari M, Izumi N, Osaki Y, Bentley R, Ochiai T, Kano T, Peck-Radosavljevic M. Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag. JHEP Rep 2021;3:100228. [PMID: 33644726 DOI: 10.1016/j.jhepr.2021.100228] [Reference Citation Analysis]
24 Park J, Jeong J, Choi HJ, Shim JW, Lee HM, Hong SH, Park CS, Choi JH, Chae MS. Role of thrombocytopenia in risk stratification for acute kidney injury after living donor liver transplantation. Platelets 2021;32:453-62. [PMID: 32299264 DOI: 10.1080/09537104.2020.1754377] [Reference Citation Analysis]
25 Maan R, van der Meer AJ, Hansen BE, Feld JJ, Wedemeyer H, Dufour JF, Zangneh HF, Lammert F, Manns MP, Zeuzem S, Janssen HL, de Knegt RJ, Veldt BJ. Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. J Hepatol 2014;61:482-91. [PMID: 24780302 DOI: 10.1016/j.jhep.2014.04.021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
26 Takada H, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Tsuchiya K, Yasui Y, Tamaki N, Takaura K, Komiyama Y, Higuchi M, Kubota Y, Wang W, Okada M, Shimizu T, Watakabe K, Enomoto N, Izumi N. Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures. PLoS One. 2019;14:e0211122. [PMID: 30768601 DOI: 10.1371/journal.pone.0211122] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
27 Eissa LA, Gad LS, Rabie AM, El-gayar AM. Thrombopoietin level in patients with chronic liver diseases. Annals of Hepatology 2008;7:235-44. [DOI: 10.1016/s1665-2681(19)31854-x] [Cited by in Crossref: 15] [Article Influence: 1.2] [Reference Citation Analysis]
28 Zhang HH, Gu GL, Zhang XY, Fan Q, Wang XY, Wei XM. Non-surgical contraindication for acute appendicitis with secondary thrombocytopenia: A case report. World J Gastroenterol 2015; 21(9): 2836-2839 [PMID: 25759558 DOI: 10.3748/wjg.v21.i9.2836] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Kim BK, Han KH, Park JY, Ahn SH, Chon CY, Kim JK, Paik YH, Lee KS, Park YN, Kim DY. External validation of P2/MS and comparison with other simple non-invasive indices for predicting liver fibrosis in HBV-infected patients. Dig Dis Sci 2010;55:2636-43. [PMID: 19960253 DOI: 10.1007/s10620-009-1070-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
30 Maan R, de Knegt RJ, Veldt BJ. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies. Drugs 2015;75:1981-92. [PMID: 26501978 DOI: 10.1007/s40265-015-0480-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
31 Giannini EG, Kano T, Ochiai T, Bentley R, Shrestha P, Afdhal N. Bleeding events in lusutrombopag-treated thrombocytopenic patients. Eur J Clin Invest 2021;51:e13503. [PMID: 33523482 DOI: 10.1111/eci.13503] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Aref S, Ibrahem L, El Menshawy N, Bassam A. Effect of splenectomy on platelets associated antibodies in hepatitis C patients with thrombocytopenia. Hematology 2012;17:118-21. [PMID: 22664051 DOI: 10.1179/102453312X13221316477705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
33 Gill H, Wong RSM, Kwong YL. From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag. Ther Adv Hematol 2017;8:159-74. [PMID: 28473904 DOI: 10.1177/2040620717693573] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
34 Louie KS, Micallef JM, Pimenta JM, Forssen UM. Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review. J Viral Hepat 2011;18:1-7. [PMID: 20796208 DOI: 10.1111/j.1365-2893.2010.01366.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
35 Huang CE, Chen YY, Chang JJ, Kuan FC, Lee KD, Lu CH, Lung J, Shen CH, Chen CC. Thrombopoietic cytokines in patients with hepatitis C virus-associated immune thrombocytopenia. Hematology 2017;22:54-60. [PMID: 27396368 DOI: 10.1080/10245332.2016.1204493] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
36 Nascimbene A, Iannacone M, Brando B, De Gasperi A. Acute thrombocytopenia after liver transplant: role of platelet activation, thrombopoietin deficiency and response to high dose intravenous IgG treatment. J Hepatol. 2007;47:651-657. [PMID: 17716776 DOI: 10.1016/j.jhep.2007.06.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
37 Giannini EG. Thrombocytopenia in patients with chronic liver disease: what's in a name? Dig Dis Sci 2013;58:299-301. [PMID: 23086124 DOI: 10.1007/s10620-012-2450-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
38 Weksler BB. Review article: the pathophysiology of th-rombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther. 2007;26 Suppl 1:13-19. [PMID: 17958515 DOI: 10.1111/j.1365-2036.2007.03512.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 4.9] [Reference Citation Analysis]
39 Afdhal N, Mchutchison J, Brown R, Jacobson I, Manns M, Poordad F, Weksler B, Esteban R. Thrombocytopenia associated with chronic liver disease. Journal of Hepatology 2008;48:1000-7. [DOI: 10.1016/j.jhep.2008.03.009] [Cited by in Crossref: 328] [Cited by in F6Publishing: 269] [Article Influence: 25.2] [Reference Citation Analysis]
40 Giannini EG, Marenco S, Fazio V, Pieri G, Savarino V, Picciotto A. Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. Liver Int. 2012;32:1113-1119. [PMID: 22471814 DOI: 10.1111/j.1478-3231.2012.02798.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
41 Cabrera Álvarez G, Madrid-marina V, Jimenez-mendez R, Leon Buitimea A, Bahena Román M, Cortez-gomez R, Reyes Esparza J, Rodríguez-fragoso L. Combined therapy with danazol, pegilated interferon, and ribavirin improves thrombocytopenia and liver injury in rats with fibrosis. Annals of Hepatology 2007;6:233-41. [DOI: 10.1016/s1665-2681(19)31904-0] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
42 Liu J, Chen J, Chen C, Wang J, Lin C, Chen P, Hung C, Kee K, Lee C, Tsai L, Chen S, Lin S, Lu S. Community-based cross-sectional study: The association of lipids with hepatitis C seropositivity and diabetes mellitus: Lipid relation HCV and diabetes mellitus. J Gastroenterol Hepatol 2012;27:1688-94. [DOI: 10.1111/j.1440-1746.2012.07212.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
43 Erickson-Miller CL, Delorme E, Tian SS, Hopson CB, Landis AJ, Valoret EI, Sellers TS, Rosen J, Miller SG, Luengo JI, Duffy KJ, Jenkins JM. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 2009;27:424-30. [PMID: 19038790 DOI: 10.1634/stemcells.2008-0366] [Cited by in Crossref: 155] [Cited by in F6Publishing: 150] [Article Influence: 12.9] [Reference Citation Analysis]
44 Ikezawa K, Naito M, Yumiba T, Iwahashi K, Onishi Y, Kita H, Nishio A, Kanno T, Matsuura T, Ono A. Splenectomy and antiviral treatment for thrombocytopenic patients with chronic hepatitis C virus infection. J Viral Hepat. 2010;17:488-492. [PMID: 19840366 DOI: 10.1111/j.1365-2893.2009.01211.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
45 Hancox SH, Smith BC. Liver disease as a cause of thrombocytopenia. QJM. 2013;106:425-431. [PMID: 23345462 DOI: 10.1093/qjmed/hcs239] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
46 Terrault N, Chen YC, Izumi N, Kayali Z, Mitrut P, Tak WY, Allen LF, Hassanein T. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. Gastroenterology. 2018;155:705-718. [PMID: 29778606 DOI: 10.1053/j.gastro.2018.05.025] [Cited by in Crossref: 79] [Cited by in F6Publishing: 64] [Article Influence: 26.3] [Reference Citation Analysis]
47 Nilles KM, Caldwell SH, Flamm SL. Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists. Hepatol Commun 2019;3:1423-34. [PMID: 31701067 DOI: 10.1002/hep4.1423] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
48 Ayadi A, Nafari AH, Sakhaee F, Rajabi K, Ghaderi Y, Rahimi Jamnani F, Vaziri F, Siadat SD, Fateh A. Host genetic factors and clinical parameters influencing the occult hepatitis C virus infection in patients on chronic hemodialysis: Is it still a controversial infection? Hepatol Res. 2019;49:605-616. [PMID: 30821879 DOI: 10.1111/hepr.13325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Afdhal NH, Esteban R. Introduction: thrombocytopenia in chronic liver disease -- treatment implications and novel approaches. Aliment Pharmacol Ther 2007;26 Suppl 1:1-4. [PMID: 17958513 DOI: 10.1111/j.1365-2036.2007.03508.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
50 Zhou L, Zhang LZ, Wang JY, Li YW, Hu HD, Peng XM, Zhao Y, Wang XM, Xie H, Liu CZ, Wang HM. Perioperative safety analysis of transcatheter arterial chemoembolization for hepatocellular carcinoma patients with preprocedural leukopenia or thrombocytopenia. Mol Clin Oncol 2017;7:435-42. [PMID: 28811901 DOI: 10.3892/mco.2017.1345] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Danish FI, Yasmin S. The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia. Hepat Med 2013;5:17-30. [PMID: 24696622 DOI: 10.2147/HMER.S27100] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
52 Zhang XH, Feng R, Xu LP, Jiang Q, Jiang H, Fu HX, Liu H, Niu T, Wang X, Hu JD, Jiang M, Wang Z, Wang JW, Ma H, Xie YD, Zhu XL, Wang H, Wei L, Huang XJ. Immunosuppressive treatment combined with nucleoside analog is superior to nucleoside analog only in the treatment of severe thrombocytopenia in patients with cirrhosis associated with hepatitis B in China: A multicenter, observational study. Platelets 2015;26:672-9. [PMID: 25397356 DOI: 10.3109/09537104.2014.979339] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
53 Gotlieb N, Schwartz N, Zelber-Sagi S, Chodick G, Shalev V, Shibolet O. Longitudinal decrease in platelet counts as a surrogate marker of liver fibrosis. World J Gastroenterol 2020; 26(38): 5849-5862 [PMID: 33132639 DOI: 10.3748/wjg.v26.i38.5849] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Kim BK, Kim do Y, Han KH, Park JY, Kim JK, Paik YH, Lee KS, Chon CY, Ahn SH. Risk assessment of esophageal variceal bleeding in B-viral liver cirrhosis by a liver stiffness measurement-based model. Am J Gastroenterol. 2011;106:1654-1652, 1730. [PMID: 21691339 DOI: 10.1038/ajg.2011.160] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
55 Rivero-Juarez A, Gonzalez R, Frias M, Manzanares-Martín B, Rodriguez-Cano D, Perez-Camacho I, Gordon A, Cuenca F, Camacho A, Pineda JA, Peña J, Rivero A. KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy. Pharmacogenomics J 2017;17:360-5. [PMID: 26975229 DOI: 10.1038/tpj.2016.19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
56 Giannini EG, Savarino V. Epidemiology of thrombocytopenia in patients with chronic hepatitis C: more than meets the eye. J Viral Hepat 2011;18:8-10. [PMID: 20796207 DOI: 10.1111/j.1365-2893.2010.01368.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
57 Shimabukuro R, Kawanaka H, Tomikawa M, Akahoshi T, Konishi K, Yoshida D, Anegawa G, Uehara H, Hashimoto N, Hashizume M, Maehara Y. Effect of thrombopoietin on platelet counts and liver regeneration after partial hepatectomy in a rat model. Surg Today 2009;39:1054-9. [DOI: 10.1007/s00595-008-4054-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
58 El-sayed R, El-ela MA, El-raziky MS, Helmy H, El-ghaffar AA, El-karaksy H. Relation of Serum Levels of Thrombopoietin to Thrombocytopenia in Extrahepatic Portal Vein Obstruction Versus Cirrhotic Children. Journal of Pediatric Hematology/Oncology 2011;33:e267-70. [DOI: 10.1097/mph.0b013e31821d80be] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
59 Nielsen NS, Jespersen S, Gaardbo JC, Arnbjerg CJ, Clausen MR, Kjær M, Gerstoft J, Ballegaard V, Ostrowski SR, Nielsen SD. Impaired Platelet Aggregation and Rebalanced Hemostasis in Patients with Chronic Hepatitis C Virus Infection. Int J Mol Sci 2017;18:E1016. [PMID: 28481325 DOI: 10.3390/ijms18051016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
60 Ghasemi A, Zadsar M, Shaiegan M, Samiei S, Namvar A, Rasouli M, Moosanejad M. Human platelet antigens polymorphisms; association to the development of liver fibrosis in patients with chronic hepatitis C. J Med Virol 2020;92:45-52. [PMID: 30729550 DOI: 10.1002/jmv.25423] [Reference Citation Analysis]
61 Brown RS. Review article: a pharmacoeconomic analysis of thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther. 2007;26 Suppl 1:41-48. [PMID: 17958518 DOI: 10.1111/j.1365-2036.2007.03505.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
62 Poordad F. Review article: thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther 2007;26 Suppl 1:5-11. [PMID: 17958514 DOI: 10.1111/j.1365-2036.2007.03510.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 4.1] [Reference Citation Analysis]
63 Chen T, Yao C, Chu I, Chuang T, Hsieh T, Hwang S. Large generation of megakaryocytes from serum-free expanded human CD34+ cells. Biochemical and Biophysical Research Communications 2009;378:112-7. [DOI: 10.1016/j.bbrc.2008.11.019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
64 Iacobellis A, Andriulli A. Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection. Expert Opinion on Pharmacotherapy 2009;10:1929-38. [DOI: 10.1517/14656560903066811] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
65 Tateishi R, Seike M, Kudo M, Tamai H, Kawazoe S, Katsube T, Ochiai T, Fukuhara T, Kano T, Tanaka K. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation. J Gastroenterol. 2018; Epub ahead of print. [PMID: 30105510 DOI: 10.1007/s00535-018-1499-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 13.3] [Reference Citation Analysis]
66 Parikh N, Nonnemacher MR, Pirrone V, Block T, Mehta A, Wigdahl B. Substance abuse, HIV-1 and hepatitis. Curr HIV Res 2012;10:557-71. [PMID: 22973853 DOI: 10.2174/157016212803306023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
67 Saray A, Mesihovic R, Vanis N, Amila M. Protein C Deficiency in Chronic Hepatitis C: Correlation With Histological Extent of Liver Fibrosis. Clin Appl Thromb Hemost 2017;23:72-7. [DOI: 10.1177/1076029615587356] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
68 Savarino E, Assandri L, Giannini EG, Savarino V. Small Intestinal Bacterial Overgrowth and Helicobacter pylori : Can They Be Cause of Thrombocytopenia in Patients With Chronic Liver Disease? American Journal of Gastroenterology 2011;106:1171-2. [DOI: 10.1038/ajg.2011.106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
69 Oh Y, Yoo SY, Choi GS, Kim G. Liver transplantation of a patient with extreme thrombocytopenia - A case report. Anesth Pain Med (Seoul) 2021;16:279-83. [PMID: 34233411 DOI: 10.17085/apm.21006] [Reference Citation Analysis]
70 Nomura T, Kubota Y, Kitanaka A, Kurokouchi K, Inage T, Saigo K, Iseki K, Baba N, Yamaoka G, Arai T. Immature platelet fraction measurement in patients with chronic liver disease: a convenient marker for evaluating cirrhotic change. Int J Lab Hematol. 2010;32:299-306. [PMID: 19694836 DOI: 10.1111/j.1751-553X.2009.01184.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
71 Mladsi D, Barnett C, Aggarwal K, Vredenburg M, Dieterich D, Kim R. Cost- Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease. Clinicoecon Outcomes Res 2020;12:515-26. [PMID: 32982341 DOI: 10.2147/CEOR.S262772] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
72 Latorre R, Vaquero J, Rincón D, Puerto M, Ponce MD, Sarnago F, Matamoros JA, Ramón E, Elizaga J, Bañares R, Ripoll C. Determinants of platelet count are different in patients with compensated and decompensated cirrhosis. Liver Int 2016;36:232-9. [DOI: 10.1111/liv.12908] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
73 Alvaro D, Caporaso N, Giannini EG, Iacobellis A, Morelli M, Toniutto P, Violi F; PReBRiC (Procedure-Related Bleeding Risk in Cirrhosis) group. Procedure-related bleeding risk in patients with cirrhosis and severe thrombocytopenia. Eur J Clin Invest 2021;51:e13508. [PMID: 33539542 DOI: 10.1111/eci.13508] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Sayyar M, Saidi M, Zapatka S, Deng Y, Ciarleglio M, Garcia-Tsao G. Platelet count increases after viral elimination in chronic HCV, independent of the presence or absence of cirrhosis. Liver Int 2019;39:2061-5. [PMID: 31365178 DOI: 10.1111/liv.14203] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
75 Nwidu LL, Elmorsy E, Oboma YI, Carter WG. Hepatoprotective and antioxidant activities of Spondias mombin leaf and stem extracts against carbon tetrachloride-induced hepatotoxicity. J Taibah Univ Med Sci 2018;13:262-71. [PMID: 31435333 DOI: 10.1016/j.jtumed.2018.03.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
76 Kamel MM, Romeyia SA, Ali MM, Aziz HA, Abdel-Moneim AS. P selectin and T cell profiles provide verification to understand the pathogenesis of liver cirrhosis in HCV and Schistosoma mansoni infections. Microb Pathog 2014;73:19-24. [PMID: 24881872 DOI: 10.1016/j.micpath.2014.05.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
77 Giannini EG, Savarino V. Thrombocytopenia in liver disease: . Current Opinion in Hematology 2008;15:473-80. [DOI: 10.1097/moh.0b013e32830a9746] [Cited by in Crossref: 62] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
78 Witters P, Freson K, Verslype C, Peerlinck K, Hoylaerts M, Nevens F, Van Geet C, Cassiman D. Review article: Blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmacol Ther. 2008;27:1017-1029. [PMID: 18331464 DOI: 10.1111/j.1365-2036.2008.03674.x] [Cited by in Crossref: 102] [Cited by in F6Publishing: 88] [Article Influence: 7.8] [Reference Citation Analysis]
79 Chin JL, Hisamuddin SH, O'Sullivan A, Chan G, McCormick PA. Thrombocytopenia, Platelet Transfusion, and Outcome Following Liver Transplantation. Clin Appl Thromb Hemost 2016;22:351-60. [PMID: 25430936 DOI: 10.1177/1076029614559771] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
80 Tripodi A, Primignani M. Nontransfusional approach to increased platelet count in patients with cirrhosis and thrombocytopenia. Hepatology 2013;58:1177-80. [PMID: 23703879 DOI: 10.1002/hep.26502] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
81 Kim BK, Han KH, Park JY, Ahn SH, Kim JK, Paik YH, Lee KS, Chon CY, Kim DY. A liver stiffness measurement-based, noninvasive prediction model for high-risk esophageal varices in B-viral liver cirrhosis. Am J Gastroenterol. 2010;105:1382-1390. [PMID: 20087336 DOI: 10.1038/ajg.2009.750] [Cited by in Crossref: 146] [Cited by in F6Publishing: 124] [Article Influence: 13.3] [Reference Citation Analysis]
82 Kim BK, Ahn SH, Han K, Park JY, Han MS, Jo JH, Kim JK, Lee KS, Chon CY, Kim DY. Prediction of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis Using the P2/MS Noninvasive Index Based on Complete Blood Counts. Digestion 2012;86:264-72. [DOI: 10.1159/000341507] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
83 Rawi S, Wu GY. Pathogenesis of Thrombocytopenia in Chronic HCV Infection: A Review. J Clin Transl Hepatol 2020;8:184-91. [PMID: 32832399 DOI: 10.14218/JCTH.2020.00007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
84 Ciurea SO, Hoffman R. Cytokines for the Treatment of Thrombocytopenia. Seminars in Hematology 2007;44:166-82. [DOI: 10.1053/j.seminhematol.2007.04.005] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
85 Agha A, Anwar E, Bashir K, Savarino V, Giannini EG. External Validation of the Platelet Count/Spleen Diameter Ratio for the Diagnosis of Esophageal Varices in Hepatitis C Virus-Related Cirrhosis. Dig Dis Sci 2009;54:654-60. [DOI: 10.1007/s10620-008-0367-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
86 Hirooka M, Ochi H, Hiraoka A, Koizumi Y, Tanaka T, Sunago K, Yukimoto A, Imai Y, Watanabe T, Yoshida O, Abe M, Joko K, Michitaka K, Hiasa Y. Role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease. J Gastroenterol Hepatol 2020;35:299-304. [PMID: 31318996 DOI: 10.1111/jgh.14786] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
87 Dusheiko G. Thrombopoietin agonists for the treatment of thrombocytopenia in liver disease and hepatitis C. Clin Liver Dis 2009;13:487-501. [PMID: 19628164 DOI: 10.1016/j.cld.2009.05.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
88 Chen JY, Wang JH, Lin CY, Chen PF, Tseng PL, Chen CH, Chang KC, Tsai LS, Chen SC, Lu SN. Lower prevalence of hypercholesterolemia and hyperglyceridemia found in subjects with seropositivity for both hepatitis B and C strains independently. J Gastroenterol Hepatol. 2010;25:1763-1768. [PMID: 21039839 DOI: 10.1111/j.1440-1746.2010.06300.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
89 Abdela J. Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag. Clin Med Insights Blood Disord 2019;12:1179545X19875105. [PMID: 31673229 DOI: 10.1177/1179545X19875105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
90 Kamel MM, Fouad SA, Basyoni MM. P selectins and immunological profiles in HCV and Schistosoma mansoni induced chronic liver disease. BMC Gastroenterol 2014;14:132. [PMID: 25066324 DOI: 10.1186/1471-230X-14-132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
91 Nguyen G, Lejeune M, Crichi B, Frere C. Hemostasis testing in patients with liver dysfunction: Advantages and caveats. World J Gastroenterol 2021; 27(42): 7285-7298 [DOI: 10.3748/wjg.v27.i42.7285] [Reference Citation Analysis]
92 Lee HS, Park SY, Kim SK, Kweon YO, Tak WY, Cho CM, Jeon SW, Jung MK, Park HG, Lee DW. Thrombocytopenia represents a risk for deterioration of liver function after radiofrequency ablation in patients with hepatocellular carcinoma. Clin Mol Hepatol. 2012;18:302-308. [PMID: 23091811 DOI: 10.3350/cmh.2012.18.3.302] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
93 Huang HH, Lin CF, Shih YL, Chang WK, Hsieh TY. Rapid development of severe thrombocytopenia in a female with chronic hepatitis C after single-dose pegylated interferon therapy. Dig Liver Dis 2010;42:233-4. [PMID: 19592316 DOI: 10.1016/j.dld.2009.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
94 Maan R, Zaim R, van der Meer AJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Manns MP, Zeuzem S, Hansen BE, Janssen H, Veldt BJ, de Knegt RJ, Uyl-de Groot CA. Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. J Gastroenterol Hepatol 2016;31:1851-9. [PMID: 26990109 DOI: 10.1111/jgh.13373] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
95 Giannini EG. Platelet count manipulation and modification of global haemostasis tests in patients with chronic liver disease: almost there, almost there…. Liver Int 2013;33:325-6. [DOI: 10.1111/liv.12105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
96 Gayam V, Mandal AK, Khalid M, Mukhtar O, Gill A, Garlapati P, Khalid M, Mansour M. Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting. Int J Hepatol 2018;2018:4136253. [PMID: 30155312 DOI: 10.1155/2018/4136253] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
97 Nilles KM, Flamm SL. Thrombocytopenia in Chronic Liver Disease: New Management Strategies. Clin Liver Dis 2020;24:437-51. [PMID: 32620282 DOI: 10.1016/j.cld.2020.04.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Takahashi K, Nagai S, Safwan M, Liang C, Ohkohchi N. Thrombocytopenia after liver transplantation: Should we care? World J Gastroenterol 2018; 24(13): 1386-1397 [PMID: 29632420 DOI: 10.3748/wjg.v24.i13.1386] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
99 Saleh MI, Melhim SB, Al-Ramadhani HM, Alzubiedi S. Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients. Eur J Drug Metab Pharmacokinet 2019;44:31-42. [PMID: 29948848 DOI: 10.1007/s13318-018-0490-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
100 Catanzaro R, Sciuto M, Lanzafame C, Balakrishnan B, Marotta F. Platelet to lymphocyte ratio as a predictive biomarker of liver fibrosis (on elastography) in patients with hepatitis C virus (HCV)-related liver disease. Indian J Gastroenterol 2020;39:253-60. [PMID: 32833144 DOI: 10.1007/s12664-020-01038-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Elbedewy TA, Elsebaey MA, Elshweikh SA, Elashry H, Abd-Elsalam S. Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia. Ther Clin Risk Manag 2019;15:269-74. [PMID: 30804674 DOI: 10.2147/TCRM.S186106] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
102 Giannini EG, Greco A, Marenco S, Andorno E, Valente U, Savarino V. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin Gastroenterol Hepatol. 2010;8:899-902; quiz e109. [PMID: 20601131 DOI: 10.1016/j.cgh.2010.06.018] [Cited by in Crossref: 103] [Cited by in F6Publishing: 80] [Article Influence: 9.4] [Reference Citation Analysis]
103 Joshi N, Kopec AK, Ray JL, Luyendyk JP. Inhibition of PAR-4 and P2Y12 receptor-mediated platelet activation produces distinct hepatic pathologies in experimental xenobiotic-induced cholestatic liver disease. Toxicology 2016;365:9-16. [PMID: 27475285 DOI: 10.1016/j.tox.2016.07.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
104 Kim BK, Kim DY, Park JY, Ahn SH, Chon CY, Kim JK, Paik YH, Lee KS, Park YN, Han KH. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int. 2010;30:546-553. [PMID: 20074094 DOI: 10.1111/j.1478-3231.2009.02192.x] [Cited by in Crossref: 144] [Cited by in F6Publishing: 142] [Article Influence: 13.1] [Reference Citation Analysis]
105 Xu X, Jin Y, Lin Y, Hu D, Zhou Y, Li D, Wang H, Jin C. Multimodal Ultrasound Model Based on the Left Gastric Vein in B-Viral Cirrhosis: Noninvasive Prediction of Esophageal Varices. Clin Transl Gastroenterol 2020;11:e00262. [PMID: 33259161 DOI: 10.14309/ctg.0000000000000262] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
106 Labidi A, Baccouche H, Fekih M, Mahjoub S, BenMustapha N, Serghini M, BenRomdhane N, Boubaker J. The relationship between coagulation disorders and the risk of bleeding in cirrhotic patients. Ann Hepatol 2019;18:627-32. [PMID: 31097395 DOI: 10.1016/j.aohep.2018.12.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
107 Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int 2017;37:778-93. [PMID: 27860293 DOI: 10.1111/liv.13317] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 13.2] [Reference Citation Analysis]
108 Galli L, Gerdes VE, Guasti L, Squizzato A. Thrombosis Associated with Viral Hepatitis. J Clin Transl Hepatol. 2014;2:234-239. [PMID: 26357629 DOI: 10.14218/jcth.2014.00031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
109 Shin SH, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis. Liver Int. 2015;35:1054-1062. [PMID: 24930484 DOI: 10.1111/liv.12621] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]